CNOOC Limited
http://www.cnoocltd.com/en/index.aspx
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CNOOC Limited
Finance Watch: Emalex Raises $250m To Fund Phase III Tourette’s Trial
Private Company Edition: The Paragon Biosciences-founded Emalex previously raised $35m when ecopipam was in Phase II. Also, Catalio Capital launches a “special situations” fund, Zenas raises $118m to develop a pipeline of autoimmune disease treatments and Lusaris emerges with $60m.
Minute Insight: Ondine Biomedical Debuts Phase 2 Preliminary Data Demonstrating Power Of Photodisinfection
Ondine Biomedical’s method of disinfection is easy to administer, cheap, and does not promote antimicrobial resistance.
Finance Watch: Latest Slate Of VC Mega-Deals Led By China-Based Biopharmas
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
Teva’s Austedo Fails In Tourette’s Syndrome
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.
Company Information
- Other Names / Subsidiaries
-
- Nexen Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice